On 3 June 2024, Warteck Invest launched its CHF 94.7 million capital increase by way of a rights offering. In the rights offering Warteck Invest shareholders were allocated subscription rights in proportion to their shareholdings in Warteck Invest. Shares not taken up by Warteck Invest shareholders were subsequently sold to investors in a share placement. Warteck Invest has issued 61,875 registered shares with a par value of CHF 10.00 each leading to gross proceeds in an amount of approximately CHF 94.7 million. The proceeds raised from the capital increase will be used to support the execution of Warteck Invest’s growth strategy and the realisation of its development projects.

On 30 May 2024, St.Galler Kantonalbank AG (SGKB) successfully issued CHF 200 million 2.4% Tier 2 bonds due 2034. Zürcher Kantonalbank acted as Sole Lead Manager and SGKB as Co-Manager.

On 22 May 2024, UBS Group AG completed its issuance of CHF 335 million in aggregate principal amount of Fixed Rate/Fixed Rate Senior Notes due May 2030. Previously, on 13 May 2024, UBS Group AG completed its issuance of USD 1.75 billion in aggregate principal amount of Fixed Rate/Fixed Rate Callable Senior Notes due September 2030 under its Senior Debt Programme. The Notes are bail-inable (TLAC) bonds that are eligible to count towards UBS Group AG’s Swiss gone concern requirement.

On 21 May 2024, UBS Switzerland AG successfully completed its issuance of Covered Bonds under the program in an aggregate principal amount of EUR 1.75 billion, consisting of EUR 1 billion Floating Rate Covered Bonds due April 2027 and EUR 750 million 3.146% Covered Bonds due June 2031. The Covered Bonds are governed by Swiss law and are listed on SIX Swiss Exchange. The Covered Bonds are indirectly backed by a portfolio of mortgages from UBS Switzerland AG’s domestic mortgage pool.

On 6 May 2024, NYSE-listed ADC Therapeutics SA, a commercial-stage biotechnology company based in Lausanne, Switzerland, announced that it had agreed to sell, by way of an underwritten offering, 13.4 million of its common shares as well as pre-funded warrants to purchase 8.1 million common shares to raise aggregate gross proceeds of approx. USD 105 million.

On 3 May 2024, Roche Finance Europe B.V. issued EUR 1.5 billion Bonds guaranteed by Roche Holding Ltd. Banco Santander S.A., BNP Paribas and UniCredit Bank GmbH acted as joint lead managers. The bonds will be listed on the SIX Swiss Exchange and have been admitted to trading on the Open Market (Freiverkehr) of the Frankfurt Stock Exchange. The transaction consists of a EUR 650 million tranche due May 2030 and a EUR 850 million tranche due May 2044.

On 18 April 2024, Dufry One B.V. issued EUR 500 m Bonds guaranteed by Avolta AG and certain of its subsidiaries. BNP Paribas, BofA Securities Europe S.A., HSBC Continental Europe S.A., ING Bank N.V., Intesa Sanpaolo S.p.A. and UniCredit Bank GmbH acted as joint global coordinators.

SIX-listed CPH Chemie + Papier Holding AG (CPH) has carried out a separation of its paper manufacturing business and related real estate in Perlen from its chemistry and packaging activities by way of spin-off and admission of the newly formed Perlen Industrieholding AG for trading on the off-exchange platforms OTC-X and LPZ-X. The purpose of the spin-off is to create two focused companies each being able to successfully pursue their own specific strategy: the SIX Swiss Exchange-listed, globally active and growth-oriented CPH (newly called CPH Group AG) with its chemistry (Zeochem) and packaging (Perlen Packaging) divisions; and off-exchange Perlen Industrieholding AG, in which are bundled the paper manufacturing business (Perlen Papier AG) and the real-estate assets of the Perlen industrial site. The spin-off was effected by way of capital reduction and distribution in kind as approved at an extraordinary shareholders meeting of CPH on 20 June 2024, pursuant to which shareholders received one share in the newly formed Perlen Industrieholding AG for each CPH share. 

On 5 March 2024, UBS Switzerland AG successfully completed its issuance under its covered bond program of EUR 1 billion 3.304% covered bonds due March 2029. The covered bonds are governed by Swiss law and have been provisionally admitted to trading on SIX Swiss Exchange, and application will be made for definitive admission to trading and listing.

On 7 March 2024, Thermo Fisher Scientific Inc. successfully completed its issuance of its inaugural CHF bonds in excess of CHF 1 billion, being the largest foreign Swiss franc bond issuance in seven years. The issuance consisted of three tranches, the CHF 330 million 1.6525 per cent. bonds due 2028, CHF 415 million 1.8401 per cent. bonds due 2032 and the CHF 325 million 2.0375 per cent. bonds due 2036. The bonds are governed by Swiss law and have been provisionally admitted to trading, and application has been made for definitive admission to trading and listing of the bonds, on the SIX Swiss Exchange. UBS Investment Bank, BNP Paribas (Suisse) SA, and Deutsche Bank AG London Branch, acting through Deutsche Bank AG Zurich Branch, acted as lead managers.